At the 35th European Academy of Dermatology and Venereology (EADV) Congress, running from September 30 to October 3, 2026, in Vienna, Neutrogena, Aveeno, and Regaine will present 12 new scientific studies. These studies focus on ingredients like niacinamide, trehalose, colloidal oat, and 5% minoxidil, highlighting their potential benefits for common skin and hair concerns such as acne, hyperpigmentation, eczema, UV damage, and androgenetic alopecia.
Read More
Kate Stockman, Vice President and Head of EMEA Research & Development at Kenvue, emphasized the impact of healthy skin and hair on consumer confidence and quality of life. The research aims to enhance understanding of how these ingredients can improve skin barrier health and promote hair regrowth.
Research on Neutrogena’s Ultra Sheer Invisible Fluid Sunscreen reveals its efficacy in managing oily skin and acne. In studies involving acne-prone Brazilian populations, the sunscreen, formulated with 2% trehalose and 2% niacinamide, led to significant reductions in visible redness (56% improvement), acne-related hyperpigmentation (46% improvement), and skin oiliness (12% reduction). Additionally, users reported a 90% satisfaction rate in decreased oiliness and improved hydration after 28 days.
Further studies on Neutrogena’s Ultra Sheer Invisible Fluid Sunscreen Hydration Fluid, comprised of 2% niacinamide and vitamins C and E, showed a 22% increase in skin hydration and notable improvements in tone and radiance over 56 days, with over 90% of participants noticing these benefits.
Aveeno’s research highlights the role of colloidal oat in skin recovery from UV damage. Clinical studies demonstrate that formulations with Aveeno’s Triple Oat Complex increased the production of skin barrier proteins and facilitated faster recovery post-UV exposure.
An international survey of dermatologists indicated strong support for colloidal oat-based emollients used alongside topical corticosteroids in eczema treatment, with 92.7% observing benefits in hydration and skin barrier support.
In a new analysis on Regaine’s 5% Minoxidil Topical Foam, researchers found that earlier intervention in treating androgenetic alopecia resulted in better hair regrowth. Younger men (ages 20 to 30) showed an average increase of 26.25 hairs after 16 weeks, compared to 19.93 hairs in older men. The study concluded that starting treatment earlier may yield more favorable results.
Additional studies reinforcing the research of Neutrogena, Aveeno, and Regaine will also be presented during the Congress, which includes an industry session sponsored by Neutrogena on hydration evidence in compromised skin. For further inquiries on the research, media representatives are available for contact.